AbbVie(US:ABBV) ZACKS·2026-01-30 15:20Core Viewpoint - Analysts expect AbbVie (ABBV) to report quarterly earnings of $2.66 per share, reflecting a year-over-year increase of 23.2%, with revenues projected at $16.36 billion, up 8.3% from the previous year [1] Earnings Estimates - Changes in earnings estimates are crucial for predicting investor reactions, with empirical research showing a strong correlation between earnings estimate revisions and short-term stock performance [2] Revenue Projections - Analysts estimate 'Net Revenue- Imbruvica' at $714.90 million, indicating a year-over-year decline of 15.7% [4] - 'Net Revenue- Botox Therapeutic- Total' is expected to reach $995.91 million, reflecting a year-over-year increase of 14.1% [4] - 'Net Revenue- Venclexta' is projected at $725.34 million, suggesting a year-over-year increase of 10.7% [4] Neuroscience and Humira Revenue - 'Net Revenue- Neuroscience- Total' is estimated at $3.00 billion, indicating a year-over-year increase of 19.5% [5] - 'Net Revenue- Humira- US' is expected to be $574.85 million, reflecting a significant decline of 53.9% from the prior year [5] - 'Net Revenue- Humira- International' is projected at $374.40 million, indicating a year-over-year decrease of 14.1% [6] Oncology and New Products - 'Net Revenue- Oncology- Elahere- Total' is expected to reach $191.62 million, reflecting a year-over-year increase of 29.5% [6] - 'Net Revenue- Epkinly- International' is projected at $48.50 million, suggesting a substantial year-over-year increase of 120.5% [6] - 'Net Revenue- Qulipta- U.S.' is estimated at $271.58 million, indicating a year-over-year increase of 46% [7] - 'Net Revenue- Qulipta- International' stands at $39.74 million, reflecting a significant year-over-year increase of 165% [8] Stock Performance - AbbVie shares have decreased by 3.5% over the past month, contrasting with the Zacks S&P 500 composite's increase of 0.9%, and the stock is expected to closely follow the overall market with a Zacks Rank 3 (Hold) [8]